Topics

Dicerna™ Submits Updated IND Application for DCR-PHXC for Treatment of Primary Hyperoxaluria (PH) for the PHYOX™2 Pivotal Trial

07:30 EDT 2 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
– Update Reflects Alignment with FDA on Path to Full Approval for Treatment of PH1 and Discussions Now Focusing on Appropriate Endpoints for PH2 and PH3 – Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Com...

Other Sources for this Article

Investors:
Stern Investor Relations, Inc.
Kendra Packard, 212-698-8688
kendra.packard@sternir.com

Media:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

NEXT ARTICLE

More From BioPortfolio on "Dicerna™ Submits Updated IND Application for DCR-PHXC for Treatment of Primary Hyperoxaluria (PH) for the PHYOX™2 Pivotal Trial"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...